Monitoring changing patterns in HER2 addiction by liquid biopsy in advanced breast cancer patients.

ABSTRACT:

Background

During targeted treatment, HER2-positive breast cancers invariably lose HER2 DNA amplification. In contrast, and interestingly, HER2 proteins may be either lost or gained. To longitudinally and systematically appreciate complex/discordant changes in HER2 DNA/protein stoichiometry, HER2 DNA copy numbers and soluble blood proteins (aHER2/sHER2) were tested in parallel, non-invasively (by liquid biopsy), and in two-dimensions, hence HER2-2D.

Methods

aHER2 and sHER2 were assessed by digital PCR and ELISA before and after standard-of-care treatment of advanced HER2-positive breast cancer patients (n=37) with the antibody-drug conjugate (ADC) Trastuzumab-emtansine (T-DM1).

Results

As expected, aHER2 was invariably suppressed by T-DM1, but this loss was surprising

SUBMITTER: Giordani E 

PROVIDER: S-EPMC11218356 | biostudies-literature | 2024 Jun

REPOSITORIES: biostudies-literature